Backgrounds: Pulmonary hypertension (PH) in idiopathic pulmonary fibrosis (IPF) is associated with poor prognosis. Recently echocardiography and brain natriuretic peptide (BNP) have been used as non-invasive markers for PH suggesting that they may also be used as markers for survival. The aim of this study was to evaluate the clinical usefulness of echocardiography and BNP by analyzing their association with survival. Methods: Retrospective review of 131 patients with IPF who underwent both echocardiography and BNP measurement at a tertiary referral center. Results: Mean follow-up period was 10.1 months. Using systolic pulmonary arterial pressure of 40 mmHg as a threshold for PH, patients with PH had poor survival (1-year mortality rate: 61.2%, mean survival: 10.8 months) than those without PH (19.9%, 23.7 months; p < 0.001). The prognosis of the subjects with increased BNP levels was poorer than those with normal BNP levels (1-year mortality rate: 70.5% vs. 23.7%, mean survival: 11.0 months vs. 22.5 months; p < 0.001) and on multivariate analysis, only BNP level was an independent predictor of prognosis. On serial evaluation, the survival of patients with newly developed PH and/or elevated BNP levels was similar to that of patients with PH at the initial measurement, suggesting that development of PH is indicative of poor prognosis regardless of the timing of the test. Conclusions: Although both BNP level and PH by echocardiography are clinically useful noninvasive and easily repeatable markers of prognosis, BNP level seems to be better. ª 2008 Elsevier Ltd. All rights reserved.
Introduction
Idiopathic pulmonary fibrosis (IPF) is a disease characterized by progressive parenchymal fibrosis of unknown etiology. 1 There is no proven effective therapy for IPF. 2 The overall prognosis is poor, with a median survival of about 3 years 3 ; however; the course of disease varies among individual patients. Several factors have been reported as prognostic predictors 4e11 : age, initial forced vital capacity (FVC), diffusion capacity (DLco), serial change in FVC, and desaturation during a 6-min walk test (6MWT). However, recent double-blind, randomized, placebo-controlled studies for IPF, 12e14 revealed that many patients succumbed without significant prior reductions in lung function. 15 Therefore, it has been suggested that, in addition to progressive fibrosis, other factors such as acute exacerbation or development of pulmonary hypertension (PH) may play an important role in the prognosis of IPF. 16e18 The development of PH is often observed in the late stages of IPF and indicates poor prognosis. Right-heart catheterization (RHC) is required for the definitive diagnosis of PH. However, RHC is invasive and difficult to perform routinely in clinical practice. Whereas transthoracic echocardiography is non-invasive and easily repeatable enabling it as a useful tool for screening or follow-up of PH. Furthermore, recently, brain natriuretic peptide (BNP) has been used as a marker of right ventricular dysfunction and pulmonary arterial hypertension 19e22 and Leuchte et al. reported that plasma BNP levels correlated well with the severity of pulmonary hemodynamic abnormality in patients with chronic lung disease. 23, 24 Therefore we hypothesized that the combination of these two non-invasive parameters may provide a better prediction of the prognosis of IPF. To test this hypothesis, we reviewed the echocardiography and BNP data of 131 patients with IPF and compared them with survival. We also evaluated the clinical value of serial measurement of sPAP and BNP during follow-up.
Materials and methods

Study populations
Echocardiography was performed in 352 patients with IPF (surgical lung biopsy, 49.1%) from September 1996 to July 2008 at the Asan Medical Center, Seoul, South Korea. Most of the subjects had been included in previous clinical studies. 25 Estimation of sPAP was possible in 261 patients (74.1%) and 14 patients were excluded owing to the presence of left ventricular dysfunction (ejection fraction < 50%) due to another cardiac problem or valvular heart disease. Among the remaining 247 patients, plasma BNP levels were also measured in 188 patients. In 131 of these patients, the measurement of plasma BNP levels and echocardiography were performed within 3-day period; these 131 patients were enrolled in this study. All subjects met the diagnostic criteria of the American Thoracic Society (ATS)/European Respiratory Society (ERS) IPF guidelines, 1 and other disorders that could cause secondary PH were excluded. Written consent was provided by each patient and the study was approved by the Institutional Review Board of the Asan Medical Center.
Methods
Clinical data were obtained from medical records and survival status was obtained from telephone interviews or medical records. Spirometry (Vmax 22; Sensormedics; Yorba Linda, CA), lung volume by plethysmography (6200 Plethysmograph; Sensormedics) and diffusion capacity for carbon monoxide (Vmax 229D; Sensormedics) were measured and the results were expressed as percentages of normal predicted values. The 6-min walk test (6MWT) was performed according to ATS guidelines with a slight modification: the technician followed the patients with continuous monitoring of oxygen saturation during the test but no additional remark or encouragement to the patient. 26 
Echocardiography
Echocardiography (Hewlett-Packard Sonos 2500 or 5500 imaging system; Hewlett-Packard Inc; Palo Alto, CA) was performed using standard transthoracic windows with a 2.5-MHz transducer. Tricuspid regurgitant flow was identified by color-flow Doppler techniques and the maximum jet velocity was measured by continuous-wave Doppler in all patients. Right atrial pressure was estimated as 5 mmHg, 10 mmHg or 15 mmHg on the basis of the size and respiratory change of the inferior vena cava (complete collapse, 5 mmHg; partial collapse, 10 mmHg; no collapse, 15 mmHg). 27 Right ventricular systolic pressure was estimated based on the modified Bernoulli equation and was considered to be equal to the sPAP in the absence of right ventricular outflow obstruction. Receiver operating characteristic (ROC) analysis revealed that a sPAP of 40 mmHg was the threshold that could be used to discriminate survivors from non-survivors and this value was used as a threshold for PH diagnosis.
BNP
Plasma BNP concentration was measured using the ADVIA Centaur â CP Immunoassay System (Siemens Medical Solution Diagnostics; Tarrytown, NY, USA). To avoid an underestimation or over-estimation of the individual values of BNP, the normalized ratio was calculated for each patient as follows: measured value divided by age-and genderadjusted normal values. Consequently, a ratio >1 indicates an increase in plasma BNP concentration. 28 
Statistical methods
All values were described as mean AE standard deviation or 95% confidence interval (CI). A chi-square test or Fisher's exact test was used for categorical data and the unpaired Student's t test or ManneWhitney U test for continuous data. Survival was evaluated using a KaplaneMeier survival curve and the log-rank test. Cox regression analysis was used to identify significant variables predicting survival. Variables selected by univariate analysis (p < 0.05) were evaluated in a multivariate analysis. ROC curve analysis was performed to compare the predictive value of sPAP and BNP. A p-value less than 0.05 was considered statistically significant (two-tailed). All data were analyzed using SPSS version 12.0 (SPSS, Inc.; Chicago, IL).
Results
Demographic features of the subjects
The mean age of the study population was 64.3 years and 73.3% were male. Mean follow-up period (from echocardiography to death or last follow-up) for the entire group was 10.1 months (median 10.4 months; range, 0.1e30.0 months) ( Table 1) . Compared with patients without PH, patients with PH had decreased FVC (% predicted), DLco, walking distance and lowest oxygen saturation (SpO 2 ) during 6MWT, and increased BNP levels (all, p < 0.05) ( Table 1) . However, when patients with increased BNP levels were compared with those with normal BNP levels, the only difference between the two groups was in the 6MWT distance (320.2 vs. 431.7 m, respectively; p Z 0.008) ( Table 1) .
Prognosis of IPF patients with pulmonary hypertension (systolic pulmonary arterial pressure greater than 40 mmHg) detected by echocardiography PH was present in 25.2% of subjects. In the patients with PH, the 1-year mortality rate (61.2%) was higher than that of the patients without PH (19.9%; p < 0.001) and mean survival time was shorter (10.8 vs. 23.7 months; p < 0.001) (Fig. 1A) . The hazard ratio of mortality in patients with PH was 4.3 (95% CI: 2.3e8.1; p < 0.001), compared with those without. When the patients were categorized into three groups according to their sPAP levels, there was a correlation between the levels of sPAP and mortality (p < 0.001) (Fig. 1B) . The 1-year mortality rates in sPAP < 40 mmHg was 19.9%, sPAP: 40e59 mmHg was 47.1% and sPAP !60 mmHg was 76.0%. The hazard ratio of mortality in the moderate-and high-sPAP groups was 2.9 (95% CI: 1.3e6.8; p Z 0.011) and 6.1 (95% CI: 2.9e12.6; p < 0.001) ( Table 2) .
Prognosis of IPF patients with elevated BNP levels BNP levels were increased in 14.5% of subjects and the mean survival time of the patients with increased BNP levels was shorter (11 months) than that of the patients with normal BNP levels (22.5 months; p < 0.001) ( Fig. 2A) . The 1-year mortality rate (70.5% vs. 23.7%; p < 0.001) was also higher in the high-BNP group and the hazard ratio of mortality was 4.1 (95% CI: 2.1e8.0; p < 0.001), compared with the normal-BNP group. When the subjects were divided into three groups according to their BNP levels, there was a correlation between the BNP levels and mortality (p < 0.001) (Fig. 2B) . The 1-year mortality rates in BNP ratio <1 was 26.4%, BNP ratio: 1e4 was 50.0% and BNP ratio !5 was 100%. The hazard ratio of mortality in the moderate-and high-BNP groups was 2.2 (95% CI: 0.9e6.0; 
Combination of echocardiography and BNP
The patients were categorized into three groups according to sPAP and BNP levels: group 1: all normal, 87 patients (66.4%); group 2: one abnormal parameter: either increased sPAP (!40 mmHg) or increased BNP, 36 patients (27.5%); group 3: all abnormal, 8 patients (6.1%). The 1-year mortality rate was greatest (100%) in group 3, followed by group 2 (51.2%) and then in group 1 (15.2%), and the differences between the groups were statistically significant (groups 1 vs. 2, p < 0.001; groups 2 vs. 3, p Z 0.009) (Fig. 3) . The hazard ratio of mortality in groups 2 and 3 was 4.4 (95% CI: 2.2e9.1; p < 0.001) and 13.8 (95% CI: 5.3e35.8; p < 0.001), respectively (Table 3) .
Serial changes in sPAP during follow-up and survival
Among 131 patients, serial echocardiography was performed in 53 patients (mean interval, 15.7 AE 17.7 months). Among these 53 patients, 17 had PH at initial echocardiography and 36 did not have PH. On follow-up echocardiography, 9 (25%) of the latter 36 patients were found to have newly developed PH. The 1-year incidence of PH was 32%. The survival of the patients with newly developed PH from the onset of PH was similar (1-year mortality: 55.6%; mean survival: 7.8 months) to that of the patients with PH at initial echocardiography (61.2%, 10.8 months; p Z 0.720). The survival of the patients persistently without PH at follow-up echocardiography analysis (1-year mortality: 18.9%; mean survival: 23.5 months) was similar to that of the patients without PH at initial echocardiography (19.9%, 23.7 months respectively). The survival of the patients with newly developed PH tends to be worse than that of patients with persistently without PH at follow-up measurement, although the difference was not statistically significant (p Z 0.061) probably due to small number of the patients.
Serial changes in BNP levels during follow-up and survival
BNP levels were measured more than twice in 62 stable patients (mean interval, 9.6 AE 7.0 months). Eleven patients had increased BNP levels at the initial measurement, and the remaining 51 patients had normal levels. Thirteen (25.5%) of these 51 patients had increased BNP levels on follow-up measurement and the 1-year incidence of increased BNP levels was 29.7%. The survival of these patients from the onset of elevation of BNP levels (1-year Figure 1 Survival curves of all subjects. A, comparison of the survival curves between the patients with sPAP ! 40 mmHg and those with sPAP < 40 mmHg. B, comparison of the survival curves of subjects stratified according to their sPAP levels. 
Evaluation of prognostic factors
Univariate analysis revealed that sPAP and BNP levels are significant predictors of mortality (Table 4) . FVC (% predicted), DLco (% predicted), TLC (% predicted), walking distance and SpO 2 nadir during 6MWT were also significant predictors of mortality. However, on multivariate analysis, only BNP levels, TLC and SpO 2 nadir during 6MWT were significant independent predictors of mortality (Table 5 ).
Discussion
The aim of this study was to identify non-invasive methods for predicting prognosis that can be used routinely in clinical practice. We found that both BNP levels and sPAP estimated by echocardiography were clinically useful indicators of poor prognosis although on multivariate analysis, only BNP level was an independent prognostic marker, suggesting the superiority of BNP level over sPAP. The combination of the two indices provided a better prediction of prognosis than either alone. Furthermore, serial sPAP and BNP level measurements, both of which can be easily performed, revealed that at any time during the disease course, increases in these parameters are predictive for poor prognosis. It is well known that PH is associated with shorter survival in patients with IPF. Using RHC, the gold-standard method, Lettieri et al. 29 found an increased 1-year mortality rate (28%) in patients with PH compared with those without PH (5.5%; p Z 0.002), and another prospective study 30 reported a higher 5-year mortality rate in patients with PH (83.3%) than in those without PH (37.8%; p < 0.001). However, its invasiveness and high costs limit the routine use of RHC in clinical practice, whereas echocardiography is a non-invasive and inexpensive method. Although echocardiography is often inaccurate and leads to considerable over-diagnosis of PH, 27 it may be used as a prognostic indicator. Nadrous et al. have reported that PH defined as estimated sPAP > 35 mmHg by echocardiography had a significant adverse impact on survival in a cohort of 88 patients. 31 In patients with sPAP > 50 mmHg, median survival was only 0.7 year, in contrast to more than 4 years in patients with sPAP < 50 mmHg. 31 Our results also showed higher 1-year mortality rate (61.2%) and shorter mean survival time in patients with sPAP ! 40 mmHg than in those with sPAP < 40 mmHg. Furthermore, the degree of sPAP was closely correlated with prognosis, as shown in Fig. 1B .
Recently, it has been known that BNP has a role not only in left ventricular failure, but also in primary pulmonary arterial hypertension and right ventricular overload after acute pulmonary embolism, and it seems to be a highly sensitive and specific indicator of poor prognosis in these patients.
19e22, 32 Leuchte et al. 23, 24 showed that plasma BNP level correlated with the severity of pulmonary hemodynamic abnormality and was a good predictor of prognosis in patients with chronic lung disease. Our study also confirmed the prognostic value of plasma BNP level, which was comparable to echocardiography. Actually multivariate analysis revealed that it is better than that of sPAP by echocardiography. Although we could not clearly demonstrate the superiority of the combination of both parameters compared to only one parameter with statistical significance because of the small numbers of the subjects with elevated sPAP and BNP level, our results suggested that a combination of BNP level and sPAP may provide a better prediction of mortality than either parameter alone suggested by higher hazard ratio. Further study including more patients is required to confirm this.
Furthermore, echocardiography and measurement of BNP levels have the advantage that they can be repeated easily. We found that the development of increased sPAP and/or BNP levels at any stage of disease course was predictive of poor prognosis, with higher 1-year mortality and shorter survival from the measurement.
Whether this increased mortality in the patients with elevated sPAP by echocardiography and/or BNP level is really due to the development of PH is not certain. It is plausible, but still remains as speculative because we could not show the direct relationship between the degree of sPAP and mortality due to inability to perform RHC.
Our study had several limitations. This was a retrospective review of patients evaluated at a single center. Our hospital is a tertiary referral center and this study was restricted to patients who underwent both echocardiography and BNP measurement within a 3-day period. Therefore, the subjects may not be representative of all IPF patients. In fact, the survival of all subjects was relatively poor (even the patients without PH), which may be due to inclusion of patients with relatively advanced disease. However, the presence of PH clearly indicated poorer prognosis when compared with patients without PH. The second limitation was a short mean follow-up period. However, it was sufficient to reveal the prognostic value of PH and elevated BNP levels. The other limitation is that RHC was not performed to confirm the presence and degree of PH resulting in over-estimation of the incidence of PH. However, our aim is not a diagnosis of PH, but the evaluation of the value of sPAP estimated by echocardiography and BNP levels as predictors of prognosis. We think this aim is clinically more important because, at present, there is no proven effective treatment for PH in patients with IPF. If an effective PH therapy with a proven survival benefit becomes available, RHC would be indicated for more accurate diagnosis of PH. Despite these limitations, our study is the first attempt to evaluate the clinical role of a combination and serial measurement of echocardiography and BNP levels in patients with IPF.
In conclusion, our data suggest that BNP levels and sPAP by echocardiography are clinically useful non-invasive and easily repeatable markers of prognosis. Although they are complementary, the BNP level seems to be better. 
